Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study

Luigi Maria Larocca, Luca Laurenti, Maria Antonietta Blasi, Giancarlo Savino, Remo Battendieri, Laura Balia, Daniela Colucci, Laura De Padua, Emilio Balestrazzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

23 Citazioni (Scopus)

Abstract

An interventional pilot study to assess the tolerability and activity of the intralesional injection of rituximab, a chimeric mAb that targets the CD20 antigen, in patients with orbital B-cell lymphoma. Five patients received four intralesional injections (one injection a week) of rituximab together with ropivicaine 2%. Side-effects and tumor response were assessed after each injection and during the follow-up (20 months). Two patients obtained complete remission of the intraorbital lesion. Two patients showed incomplete response after induction therapy and received planned escalating rituximab doses, obtaining regression of subjective symptoms. One patient did not achieve tumor regression after the first injection and underwent systemic treatment. This small exploratory study suggests that intralesional rituximab is a well-tolerated treatment for patients with primary ocular adnexal lymphoma. These preliminary findings suggest that intralesional rituximab is a well-tolerated strategy in anterior intraorbital lesion localization of lymphoma.
Lingua originaleEnglish
pagine (da-a)1565-1567
Numero di pagine3
RivistaCancer Science
Volume102
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Aged
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Female
  • Humans
  • Infusions, Intralesional
  • Lacrimal Apparatus
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Male
  • Middle Aged
  • Orbital Neoplasms
  • Pilot Projects

Fingerprint

Entra nei temi di ricerca di 'Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study'. Insieme formano una fingerprint unica.

Cita questo